[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800-466-6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 70, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 62, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1006234, "exercisedValue": 0, "unexercisedValue": 228334}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 63, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 677467, "exercisedValue": 0, "unexercisedValue": 52440}, {"maxAge": 1, "name": "Ms. Laura  Kavanaugh", "title": "VP & Head of Legal", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristina  Engeseth M.B.A.", "title": "Senior VP and Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 57, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "Senior VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hardean E. Achneck M.D.", "age": 47, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kieron  Wesson Ph.D.", "title": "Vice President & Head of Chemistry Manufacturing Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ramon  Polo M.B.A., Ph.D., Pharm.D.", "title": "Senior VP & Head of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.24, "open": 10.18, "dayLow": 9.6, "dayHigh": 10.18, "regularMarketPreviousClose": 10.24, "regularMarketOpen": 10.18, "regularMarketDayLow": 9.6, "regularMarketDayHigh": 10.18, "payoutRatio": 0.0, "beta": 2.774, "forwardPE": -0.8447986, "volume": 86672, "regularMarketVolume": 86672, "averageVolume": 74256, "averageVolume10days": 78730, "averageDailyVolume10Day": 78730, "bid": 7.26, "ask": 10.17, "bidSize": 2, "askSize": 1, "marketCap": 70000336, "fiftyTwoWeekLow": 3.76, "fiftyTwoWeekHigh": 46.8, "allTimeHigh": 937.75, "allTimeLow": 3.76, "priceToSalesTrailing12Months": 22.054296, "fiftyDayAverage": 9.4288, "twoHundredDayAverage": 13.619225, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -54122664, "profitMargins": 0.0, "floatShares": 3001994, "sharesOutstanding": 6151374, "sharesShort": 292427, "sharesShortPriorMonth": 302609, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.0421, "heldPercentInsiders": 0.1037, "heldPercentInstitutions": 0.54145, "shortRatio": 3.94, "shortPercentOfFloat": 0.0484, "impliedSharesOutstanding": 6951374, "bookValue": 16.56, "priceToBook": 0.6080918, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -74184000, "trailingEps": -13.27, "forwardEps": -11.92, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": -17.052, "enterpriseToEbitda": 0.698, "52WeekChange": 0.34266663, "SandP52WeekChange": 0.17904854, "quoteType": "EQUITY", "currentPrice": 10.07, "targetHighPrice": 175.0, "targetLowPrice": 36.0, "targetMeanPrice": 80.25, "targetMedianPrice": 55.0, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 122945000, "totalCashPerShare": 19.987, "ebitda": -77562000, "totalDebt": 6878000, "quickRatio": 6.067, "currentRatio": 6.314, "totalRevenue": 3174000, "debtToEquity": 6.752, "revenuePerShare": 0.405, "returnOnAssets": -0.40297002, "returnOnEquity": -0.87741995, "grossProfits": -58109000, "freeCashflow": -44316000, "operatingCashflow": -74917000, "revenueGrowth": -0.09, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -19.24041, "financialCurrency": "USD", "symbol": "ALGS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "regularMarketPrice": 10.07, "regularMarketChangePercent": -1.66016, "longName": "Aligos Therapeutics, Inc.", "messageBoardId": "finmb_581475891", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Aligos Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1759526283, "regularMarketTime": 1759521601, "exchange": "NCM", "postMarketChangePercent": 0.0, "postMarketPrice": 10.07, "postMarketChange": 0.0, "regularMarketChange": -0.17, "regularMarketDayRange": "9.6 - 10.18", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 74256, "fiftyTwoWeekLowChange": 6.3099995, "fiftyTwoWeekLowChangePercent": 1.6781913, "fiftyTwoWeekRange": "3.76 - 46.8", "fiftyTwoWeekHighChange": -36.73, "fiftyTwoWeekHighChangePercent": -0.7848291, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1602855000000, "fiftyTwoWeekChangePercent": 34.266663, "earningsTimestamp": 1754510400, "earningsTimestampStart": 1762372800, "earningsTimestampEnd": 1762372800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -13.27, "epsForward": -11.92, "epsCurrentYear": -7.88, "priceEpsCurrentYear": -1.2779187, "fiftyDayAverageChange": 0.64120007, "fiftyDayAverageChangePercent": 0.06800442, "twoHundredDayAverageChange": -3.5492249, "twoHundredDayAverageChangePercent": -0.26060402, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-16", "cryptoTradeable": false, "displayName": "Aligos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-10-04"}]